Clinical Trial Update: Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and tolerability study of SG2000 for advanced chronic lymphocytic leukemia and acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia

Drugs mentioned

• SG2000

Snippet

Sponsor: Spirogen | Conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED